In line with inhibitory properties of B7-H4, anti-B7-H4-blocking antibodies showed encouraging preclinical anti-tumor efficacy.257,260,261 Anti-B7-H4 mAb has entered clinical trials including first-in-class antibody alsevalimab and NC762 (Table 1 and Supplementary Table 1). This evidence concerns the gene VTCN1 and neoplasm.